Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study

Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study

Abstract Palbociclib is a highly selective, reversible, oral inhibitor of cyclin‐dependent kinases 4 and 6 that is approved to treat hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer. An open‐label, single‐arm, Japanese phase 2 study was conducted to...

Full description

Bibliographic Details
Main Authors: Masato Takahashi, Norikazu Masuda, Reiki Nishimura, Kenichi Inoue, Shinji Ohno, Hiroji Iwata, Satoshi Hashigaki, Yasuaki Muramatsu, Yoshiko Umeyama, Masakazu Toi
Format: Article
Language:English
Published: Wiley 2020-07-01
Series:Cancer Medicine
Subjects:
advanced breast cancer
cyclin‐dependent kinase
Japanese
letrozole
palbociclib
Online Access:https://doi.org/10.1002/cam4.3091

Internet

https://doi.org/10.1002/cam4.3091

Similar Items